Biotech 2050 Podcast

Revolutionizing CAR T with CRISPR: Rachel Haurwitz, President & CEO of Caribou Biosciences


Listen Later

Synopsis:
Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of the biggest challenges in biotech.
With four ongoing Phase 1 trials in lymphoma, multiple myeloma, AML, and lupus, Caribou is leading the charge in making CAR T therapies more scalable, accessible, and cost-effective. Rachel also discusses Caribou’s journey from a private startup to a publicly traded company, the role of strategic partnerships like Pfizer’s equity investment, and how biotech companies can navigate today’s uncertain funding landscape.
She reflects on lessons from co-founding Caribou at just 26, the evolution of biotech entrepreneurship, and why raising more capital than you think you need is crucial. Plus, she shares her perspective on leadership, industry trends, and the importance of diversity in biotech, as seen during JPMorgan’s ‘Pink Tuesday’ movement.
From cutting-edge science to strategic decision-making, this episode is packed with insights for biotech professionals, investors, and anyone fascinated by the future of gene editing and cell therapy.
Biography:
Rachel is a co-founder of Caribou Biosciences and has been its president and chief executive officer and a director since the company’s inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors for Biotechnology Innovation Organization (BIO). Rachel earned an AB in biological sciences from Harvard College and a PhD in molecular and cell biology from the University of California, Berkeley.
...more
View all episodesView all episodes
Download on the App Store

Biotech 2050 PodcastBy Biotech 2050

  • 4.7
  • 4.7
  • 4.7
  • 4.7
  • 4.7

4.7

59 ratings


More shows like Biotech 2050 Podcast

View all
WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,715 Listeners

Exchanges by Goldman Sachs

Exchanges

981 Listeners

The Knowledge Project with Shane Parrish by Shane Parrish

The Knowledge Project with Shane Parrish

2,659 Listeners

Odd Lots by Bloomberg

Odd Lots

1,842 Listeners

Masters of Scale by WaitWhat

Masters of Scale

3,990 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

121 Listeners

The Readout Loud by STAT

The Readout Loud

316 Listeners

The Intrinsic Value Podcast - The Investor’s Podcast Network by The Investor's Podcast Network

The Intrinsic Value Podcast - The Investor’s Podcast Network

558 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

88 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

30 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

144 Listeners

Business Breakdowns by Colossus | Investing & Business Podcasts

Business Breakdowns

352 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

18 Listeners

The So What from BCG by Boston Consulting Group BCG

The So What from BCG

220 Listeners

HBR On Leadership by Harvard Business Review

HBR On Leadership

155 Listeners